Hemp Extract, Positive Urine Screening and Unquantifiable Plasma THC
A positive urine cannabis screen and an unquantifiable plasma THC result can occur together without the cause of the disagreement being established. An exploratory hemp-extract study shows why neither result should be rewritten to make the evidence appear more consistent than it is.
Two routes and two kinds of evidence
Jain and colleagues enrolled healthy adults in a randomized, open-label crossover study of a specific hemp-extract product administered orally or topically. Plasma cannabinoids were assessed by LC–MS/MS. Urine was assessed with commercial screening strips. Twenty participants enrolled, with 18 completing both periods.
Oral administration produced greater observed CBD exposure than topical use. Some participants had positive urine cannabinoid screens after oral administration, while plasma THC-related analytes remained below quantification limits. The study did not establish that those urine screens proved THC formation inside the body.
The missing baseline matters
The authors acknowledge that urine was not tested before product administration. Without a pre-exposure urine result, the study cannot show that every postdose positive first appeared because of the study product. A plausible explanation and a demonstrated causal explanation are different things.
Likewise, a screening strip and a quantitative mass-spectrometric assay in another matrix do not measure the same thing. Cross-reactivity, analytical thresholds, prior exposure, and specimen timing require examination; the study did not conclusively resolve the mechanism.
Below quantification is not a universal zero
A result below the assay’s quantification limit means the method could not reliably quantify that analyte under the specified conditions. It does not establish absence at every earlier time. Conversely, a positive urine strip is not a quantitative plasma THC measurement or proof of contemporaneous intoxication.
Applying the study without overreaching
In a disputed result, obtain the actual product and lot, route, use history, predose specimens if available, screening identity, confirmation, and each assay’s limits. The formulation-specific findings should not be extended to every hemp product or every topical preparation.
The study also had limited late sampling, constraining terminal pharmacokinetic estimates, and was funded by the product manufacturer. Its evidence supports careful examination of discordant results, not a blanket guarantee that a CBD product will or will not trigger a cannabis test.
Related evidence
See our related analysis of toxicology evidence and its limits.
Primary research
Results of an Exploratory Crossover Pharmacokinetic Study Evaluating a Natural Hemp Extract-Based Cosmetic Product: Comparison of Topical and Oral Routes of Administration. Pharmaceuticals, 2026. DOI: 10.3390/ph19020231.
